1138 results about "Cerebral infarction" patented technology

A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron is disclosed. The method comprises administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor—neuronal protein interaction. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity, ischemic and traumatic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults, dramatically reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia, and traumatic brain injury (TBI) in rats.

A oral-cavity effervescent talbet for treating cardiovascular and cerebrovascular diseases, such as coronary heart disease, angina pectoris, cerebral thrombosis, cerebral infarction, etc. is prepared from breviscapine, diluent, disintegrant, effervescent agent, flavouring, flowing aid,and lubricant.

An agent for treating overactive bladder resulting from cerebral infarction, comprising administrating a compound having a cholinesterase inhibitory activity or a pharmacologically acceptable salt thereof.

The invention discloses a new traditional Chinese medicine composition for treating cerebral thrombosis and cerebral infarction and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following Chinese medicinal herbs such as dutchmanspipe root, fruit of immature citron, dried orange peel, pangolin scales, ground beeltle, ligusticum wallichii, cassia twig, angelica sinensis, radix paeoniae alba, root of red-rooted salvia, agilawood, rhizoma cyperi, rhizoma corydalis, radix curcumae, pseudo-ginseng, common burreed rhizome, curcuma zedoary, red flower, peach kernel, rhizoma gastrodiae, uncaria rhynchophylla, white muscardine silkworm, scorpio, styrax asiatic styrax and rhizoma acori graminei. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve the symptoms of aphasia from apoplexy, facial paralysis, numb hands and feet, blindness, dizziness and faint, hypertension, blood viscosity increase, insufficiency of cerebral blood supply and the like, and has accurate clinical treatment effect, remarkable treatment effect and rapid effect. The traditional Chinese medicine composition has the advantages of low cost, basically no toxic or side effects and the like.

The invention relates to a traditional Chinese medicine for treating cardiac, cerebral and vascular diseases; the drug is composed of forty kinds of crude drugs by weight parts: milk veteh, salvia miltiorrhiza, root of common peony, ligusticum wallichii, lumbricus, sanguisuga, rhizoma acori graminei, polygala root, red ocher, oyster, angelica, the root of kudzu vine, arisaema cum bile and the like; the preparation method is that: (1) the crude drugs are prepared into water extract liquid; (2) the water extract liquid is prepared into oral liquid; (3)the water extract liquid obtained by the step (1) is dried, crushed, sieved, undersize material is extracted powder; (4) the extracted powder prepared by the step (3) is prepared into various dosage forms. The preparation method of crude powder is that: lime earth of the crude drugs is sieved, and then the crude drugs are crushed and sieved, the undersize material is taken out and is sterilized to be crude powder, and the crude powder is prepared into various dosage forms. The traditional Chinese medicine has the major functions of treating miocardial infarction and angina caused by coronary heart disease, high blood pressure and cerebral thrombosis, hemiplegia, cerebral infarction, cerebrovascular accident, sequel of apoplexy and other symptoms, and the medicine has obvious effect on headache, dizziness and heart cerebrovascular diseases caused by high blood pressure and cerebral circulation insufficiency.

The present invention provides a therapeutic agent containing as an active ingredient an HGF gene used for therapy of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, spinal cord injury, diabetic peripheral neuritis, and ischemic cerebrovascular disorders (cerebral infarction, cerebral haemorrhage, etc.) More specifically, the present invention provides a therapeutic agent for neurodegenerative diseases, containing a hepatocyte growth factor (HGF) gene as an active ingredient.

In accordance with the invention, a compound with a protective action for nerve cell can be reselected by adding PPARδ agonist to a culture cell system where toxic substances such as thapsigargin, MPP⁺ and staurosporine are preliminarily allowed to react and reselecting a compound improving the survival rate. The compound selected by such method can be used as an active ingredient of a therapeutic agent for neurodegenerative diseases such as cerebral infarction and Parkinson's disease. Thus, the invention is very useful for research works for creating novel pharmaceutical agent.

The present invention relates to the new use of narigenin and similar compounds in preparing medicines for treating cardiac and cerebral vascular diseases. These compounds include narigenin and its derivative, hesperidene and its derivative, isosakuranetin and its derivative, eriodictyol and its derivative, etc. These compounds may be used in preventing, diagnosing and treating cerebral infarction, myocardial infarction, cerebral ischemia-reperfusion injury, myocardial ischemia-reperfusion injury and other cardiac and cerebral vascular diseases as well as Alzheimer disease and its relevant diseases. These compounds have high pharmacological action, low toxicity, wide material source, low cost and other advantages.

The invention discloses a compound with thrombolytic activity as well as a preparation method and an application as the thrombolytic agent thereof. The 2-nitrogen or the 3-carboxyl of cyclized dopa is respectively coupled or latticed with H-Ala-Arg-Pro-Ala-Lys-OH, H-Pro-Ala-Lys-OH, H-Arg-Pro-Ala-Lys-OH, H-Gly-Arg-Pro-Ala-Lys-OH or H-Gln-Arg-Pro-Ala-Lys-OH to obtain the compound. The thrombolytic activity of the compound is evaluated by adopting the model of artery-vein bypass cannula thrombus in rats, and the experimental result shows that the compound has the excellent thrombolytic activity and can be clinically used as the thrombolytic agent. The therapeutic action of the compound to the cerebral infarction is further evaluated by adopting the model of cerebral thrombus in rats, and the experimental result shows that the compound has the excellent brain tissue protection action and can be clinically used as the thrombolytic agent.

The invention discloses a GRPAK/tetrahydroglyoxaline/RGD ternary conjugate as well as a preparation method and application of the GRPAK/tetrahydroglyoxaline/RGD ternary conjugate. According to the preparation method, L-Lys is served as a link arm, and 1, 3-dioxo-2-[(4-peracetic acid) phenyl]-4, 4, 5, 5-tetramethyl tetrahydroglyoxaline, the GRPAK pentapeptide with a thrombolytic effect, and RGD tetrapeptide with an antithrombosis effect are integrally linked, thus obtaining the GRPAK/tetrahydroglyoxaline/RGD ternary conjugate as shown in formula I. The GRPAK/tetrahydroglyoxaline/RGD ternary conjugate disclosed by the invention has high activity on removing NO free radical, excellent thrombolytic activity and antithrombosis activity; as in-vivo apoplexy activity shown, the GRPAK/tetrahydroglyoxaline/RGD ternary conjugate can effectively protect the neurologic function of a rat subjected to apoplexy, and reduces the brain infarct volume of the rat subjected to apoplexy, and has high apoplexy resisting activity, and can be prepared into a clinical medicine for treating apoplexy or cerebral infarction.

Method is provided of treating or preventing hypertrophy, hypertension, myocardial ischemia, ischemic heart disease, myocardial infarction, congestive heart failure, organ ischemia, tissue ischemia, acute coronary syndrome, unstable angina, ischemia reperfusion injury, preventing death subsequent to myocardial infarction, cerebral infarction, contractile dysfunction subsequent to myocardial infarction, or arrhythmia in a mammal with low doses of pyridoxine, pyridoxal-5′phosphate, pyridoxal or pyridoxamine. Compositions and kits for said method is also included.

Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

The present invention relates to the field of medical technology, and in particular relates to a category of novel sulphonyl substituted xanthene ketone compounds that have a structural formula as shown in the right, a preparation method and application thereof. The compound has high inhibitory activity for ACAT1/ACAT2; most of the compounds have high inhibitory activity for acyl coenzyme A cholesterol acyltransferase (ACAT). The compounds can be used for preparing anti-atherosclerosis drug combination. Furthermore, the compounds can be used as a preventive or a treating agent of such diseases as angina, myocardial infarction, cerebral infarction, apoplexy, Alzheimer's disease, acute coronary syndrome, PTCA or restenosis of coronary artery after a bracket is arranged. The compounds can be used as a treating agent to adjust the function of sebaceous glands of the skin and inhibit the excessive generation of sebum. And the compounds can be used for treating such diseases as acne-like damage caused by oily skin, acne, seborrhea and corticosteroids.

This invention relates to natual medicine chemical and medical technique field. It discloses two kind celosin new compounds of celosin A and celosin B structure and its distillation and eperating method from amaranthcea plant celosin. Their chemical general formula is shown as formula (1). This invention also discloses the compound and its derivative medicine aspect application of curing and preventing fatty liver, liver injury, hepatic fibrosis, liver cirrhosis, coronary heart disease, cardiac infarction, myocardial ischemia, cerebral ischemia, cerebral infarction, cerebral apoplexy, diabetes mellitus, hyperinsulinism, insulin resistance disease, obesity, glucose intolerance capability, and/or hypertension adiposity, hyperlipemia, dementia, depression or anxiety, and insomnia diseases.

The embodiment of the invention provides a data processing method and device. On one hand, the method comprises the following steps that: according to grey information in obtained diffusion-weighted imaging image data of different b values, automatically segmenting a high-lightness area to determine a cerebral infarction area; according to obtained perfusion weighted imaging image data, utilizing an appointed algorithm to obtain perfusion parameter image data; utilizing the perfusion parameter image data and an obtained anatomy map, determining an ischemic area; carrying out image registration on the diffusion-weighted imaging image data and the perfusion weighted imaging image data; and then, on the basis of a registration result, obtaining the mismatching information of the cerebral infarction area and the ischemic area. In the embodiment of the invention, through the above operations, the cerebral infarction area and the ischemic area can be determined, and since a doctor does not need to analyze the perfusion weighted imaging image data or the weighted imaging image data and does not need to manually determine the cerebral infarction area or the ischemic area, duration consumed for confirming the cerebral infarction area and the ischemic area can be shortened.

An ethylester of fatty acid containing high-content and-purity DHA and high-purity EPA, especially EPA-E and DHA-E in weight ratio of 1: (1.01-38), a medicine prepared from it for preventing and treating hyperlipemia, angina pectoris and cerebral infarction, and its preparing process are disclosed.

Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Disclosed is a therapeutic material for cerebral infarction, which can recover a vascular disorder in an area affected by cerebral infarction to improve the brain function. The therapeutic material for cerebral infarction includes a dental pulp stem cell comprising at least one member selected from a CD105-positive cell, an SP cell, a CD24-positive cell, a CD133-positive cell, a CD271-positive cell and a CD150-positive cell. The therapeutic material may additionally include a protein secreted from a dental pulp cell. A transplanted dental pulp stem cell cannot be differentiated directly into a neural progenitor cell or a neurocyte, but is involved indirectly in the promotion of differentiation to eliminate an area affected by cerebral infarction, thereby recovering the affected area into a normal area.

The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.